Adage Capital Partners
CBIO

Adage Capital Partners’s Crescent Biopharma CBIO Stock Holding History

Adage Capital Partners’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-200,005
Closed -$2.38M – 951
2025
Q3 		$2.38M Buy
200,005
+99,093
+98% +$1.31M ﹤0.01% 796
2025
Q2 		$1.63M Buy
100,912
+50,000
+98% +$1.06M ﹤0.01% 774
2025
Q1 		$1.07M Hold
50,912
– – ﹤0.01% 789
2024
Q4 		$1.27M Buy
+50,912
New +$1.39M ﹤0.01% 810
2024
Q2 		– Sell
-1,000
Closed -$300K – 897
2024
Q1 		$300K Hold
1,000
– – ﹤0.01% 815
2023
Q4 		$236K Buy
+1,000
New +$155K ﹤0.01% 788

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Adage Capital Partners's CBIO Position: Q4 2025 in Review

Adage Capital Partners sold out of Crescent Biopharma (CBIO) in Q4 2025, closing a stake of 200,005 shares — an estimated $2.38M sold.

Adage Capital Partners first reported a position in CBIO in Q4 2023 and held it in 6 quarters. The position peaked at $2.38M in Q3 2025. 58 funds tracked by Wall St. Rank hold CBIO as of Q4 2025.

  • Adage Capital Partners reported no remaining Crescent Biopharma position as of Q4 2025 after selling out during the quarter.
  • Adage Capital Partners sold 200,005 Crescent Biopharma shares in Q4 2025, an estimated $2.38M.
  • Adage Capital Partners first reported a position in Crescent Biopharma in Q4 2023 and held it in 6 quarters.
  • Adage Capital Partners's Crescent Biopharma position peaked at $2.38M in Q3 2025.
  • 58 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2025.

Based on Adage Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.